Review summary
Teaching objective: Evaluate postmenopausal bleeding at once, as any bleeding after menopause requires, in a 60-year-old Black woman, whose risk of dying of endometrial cancer is about twice that of White women because of later diagnosis, more aggressive non-endometrioid and p53-abnormal tumors, and delays in evaluating bleeding: transvaginal ultrasound together with endometrial sampling at the first evaluation (the ACOG update that no longer relies on a thin endometrium alone); histology with the molecular classification (POLE, mismatch repair, p53) that the FIGO 2013 staging uses; CT staging; gynecologic oncology care with minimally invasive hysterectomy and sentinel lymph node mapping; treatment chosen by stage and molecular class, here dostarlimab with carboplatin and paclitaxel for mismatch repair deficient stage IIIC2 disease, with immune-related adverse event monitoring; universal Lynch syndrome tumor screening with MLH1 promoter methylation testing and genetic counseling; and survivorship care, on the NCCN uterine neoplasms guideline, the ACOG postmenopausal bleeding guidance, the SGO surveillance statement and the CMID endometrial cancer monograph.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| September 29, 1955 | Born in Queens, New York. | CLM-0001 |
| 1977 | Graduates from Simmons College; hired by the Boston Herald American. | CLM-0002 |
| 1999 | Becomes moderator of Washington Week in Review and a NewsHour senior correspondent. | CLM-0003 |
| 2004 | Moderates the vice-presidential debate and asks about AIDS among Black women. | CLM-0004 |
| 2009 | Publishes The Breakthrough. | CLM-0004 |
| 2013 | Named co-anchor of the PBS NewsHour. | CLM-0003 |
| April 7, 2016 | Announces a leave of a few weeks for health reasons; returns by the start of June. | CLM-0005 |
| November 14, 2016 | Dies at a hospice in Washington, D.C., at 61; her family gives the cause as endometrial cancer, and friends describe a diagnosis at the turn of the year and treatment kept private. | CLM-0006, CLM-0007 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Gwendolyn Ifill was born in Queens, New York, on September 29, 1955, the fifth of six children. Her father, a Panamanian immigrant, became a pastor in the African Methodist Episcopal Church; her mother was from Barbados. The family moved around the Northeast for her father's work and for a time lived in federally subsidized housing. | confirmed | Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) supports HISTMED Master Roster v3 context |
| D | She graduated from Simmons College in Boston in 1977. As a college intern at the Boston Herald American she found a racist note left for her; the paper's editors hired her after she graduated. She went on to report for the Baltimore Evening Sun, The Washington Post, The New York Times and NBC News. Anchors the modern social history: a journalist who met racism early in her career and built one of the most respected careers in American news. |
confirmed | Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) supports Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) supports |
| D | In 1999 she became moderator of PBS's Washington Week in Review, the first African American woman to host a major national political talk show, and a senior correspondent for the NewsHour. In 2013 she and Judy Woodruff were named co-anchors of the PBS NewsHour, the first women to jointly lead a national nightly news broadcast. Her work as an anchor and moderator anchors the modern social history. |
confirmed | Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) supports Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports Remembering Gwen supports Ehrbar N. Gwen Ifill, "PBS NewsHour" anchor, is dead at 61 supports |
| D | She moderated the vice-presidential debates of 2004 and 2008. In the 2004 debate she asked the candidates about AIDS in the United States, citing the much higher death rate among Black women aged 25 to 44. She wrote The Breakthrough: Politics and Race in the Age of Obama (2009). Her question in the 2004 debate drew national attention to a health disparity affecting Black women; the modern episode teaches another one. |
confirmed | Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) supports Remembering Gwen supports |
| D | On April 7, 2016, she told viewers she would be off the air for a few weeks; PBS described the reason as health issues it did not specify, and in May said she was doing well and expected to return around Memorial Day. She was back on the air by the start of June, when she interviewed President Obama. The first public sign of her illness, three months after the modern index visit. The illness itself was not named in public until her death. |
confirmed | PBS' Gwen Ifill, on leave, expected to return in 2 weeks (The Associated Press) supports Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) supports Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) context |
| D | She kept her illness private. After her death a close friend said she had been diagnosed with cancer at the end of 2015 or early in 2016, had told family and friends, and that the April leave was due to complications of treatment; another friend described her keeping up her work through chemotherapy. PBS said she died after several months of cancer treatment. The anchor for the modern episode. These are friends' accounts and an official statement given after her death; the stage, histology and treatment of her cancer were never made public. |
probable | Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) supports Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports Ehrbar N. Gwen Ifill, "PBS NewsHour" anchor, is dead at 61 supports Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) supports |
| D | She took a second leave shortly before her death and died at a hospice in Washington, D.C., on November 14, 2016, at 61. Her family gave the cause as endometrial cancer. The documented disease to which the synthetic diagnosis is linked. History only, stated without detail. |
confirmed | Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) supports Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) supports Remembering Gwen supports Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked | resolved | confirmed | active | CLM-0006 |
| S | Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial cancer | active | confirmed | both_with_link | CLM-0006, CLM-0007 |
| S | Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2013 stage IIIC2ii | active | confirmed | active | |
| S | Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes, grade 1 (sensory only, no effect on daily activities) | active | confirmed | active | |
| S | Immune-related primary hypothyroidism from dostarlimab: TSH 11.8 with a low free T4, tiredness and feeling cold (grade 2) | active | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2016-01-05 | Hemoglobin [Mass/volume] in Blood | 11.8 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2016-01-05 | Leukocytes [#/volume] in Blood by Automated count | 6.2 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2016-01-05 | Platelets [#/volume] in Blood by Automated count | 268 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2016-01-05 | Creatinine [Mass/volume] in Serum or Plasma | 0.82 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2016-01-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2011)/1.73 sq M | 82 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2016-01-05 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2016-01-05 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5% Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes |
http://loinc.org · 4548-4 |
| S | 2016-01-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2016-01-20 | Hemoglobin [Mass/volume] in Blood | 12.1 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2016-01-20 | Leukocytes [#/volume] in Blood by Automated count | 6 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2016-01-20 | Neutrophils [#/volume] in Blood by Automated count | 3.6 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2016-01-20 | Platelets [#/volume] in Blood by Automated count | 274 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2016-01-20 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2016-01-20 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2016-01-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2016-01-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2011)/1.73 sq M | 84 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2016-01-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2016-01-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 2016-01-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2016-01-20 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2016-01-20 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 28 U/mL Reference <=35 U/mL |
http://loinc.org · 10334-1 |
| S | 2016-01-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2016-01-20 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | http://loinc.org · 70274-6 |
| S | 2016-02-24 | Hemoglobin [Mass/volume] in Blood | 11.6 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2016-02-24 | Leukocytes [#/volume] in Blood by Automated count | 6.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2016-02-24 | Neutrophils [#/volume] in Blood by Automated count | 3.9 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2016-02-24 | Platelets [#/volume] in Blood by Automated count | 301 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2016-02-24 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2016-02-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2011)/1.73 sq M | 87 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2016-02-24 | Glucose [Mass/volume] in Serum or Plasma | 92 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2016-02-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2016-02-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 2016-02-24 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2016-02-24 | Albumin [Mass/volume] in Serum or Plasma | 4 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2016-02-24 | Magnesium [Mass/volume] in Serum or Plasma | 2 mg/dL Reference 1.7-2.2 mg/dL |
http://loinc.org · 19123-9 |
| S | 2016-02-24 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 mIU/L Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2016-02-24 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2016-02-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 2016-04-28 | Hemoglobin [Mass/volume] in Blood | 10.6 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2016-04-28 | Leukocytes [#/volume] in Blood by Automated count | 4.3 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2016-04-28 | Neutrophils [#/volume] in Blood by Automated count | 2.1 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2016-04-28 | Platelets [#/volume] in Blood by Automated count | 196 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2016-04-28 | Creatinine [Mass/volume] in Serum or Plasma | 0.81 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2016-04-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2011)/1.73 sq M | 83 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2016-04-28 | Glucose [Mass/volume] in Serum or Plasma | 97 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2016-04-28 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2016-04-28 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 2016-04-28 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2016-04-28 | Magnesium [Mass/volume] in Serum or Plasma | 1.8 mg/dL Reference 1.7-2.2 mg/dL |
http://loinc.org · 19123-9 |
| S | 2016-04-28 | Thyrotropin [Units/volume] in Serum or Plasma | 4.8 mIU/L (high) Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2016-04-28 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2016-04-28 | Cortisol [Mass/volume] in Serum or Plasma | 12.6 ug/dL Reference Morning sample, drawn before 9 a.m. |
http://loinc.org · 2143-6 |
| S | 2016-04-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 2016-06-30 | Hemoglobin [Mass/volume] in Blood | 11.4 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2016-06-30 | Leukocytes [#/volume] in Blood by Automated count | 4.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2016-06-30 | Neutrophils [#/volume] in Blood by Automated count | 2.8 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 2016-06-30 | Platelets [#/volume] in Blood by Automated count | 228 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2016-06-30 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2016-06-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2011)/1.73 sq M | 80 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2016-06-30 | Glucose [Mass/volume] in Serum or Plasma | 90 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2016-06-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2016-06-30 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 2016-06-30 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2016-06-30 | Thyrotropin [Units/volume] in Serum or Plasma | 11.8 mIU/L (high) Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2016-06-30 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.7 ng/dL (low) Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2016-06-30 | Cortisol [Mass/volume] in Serum or Plasma | 13.1 ug/dL Reference Morning sample, drawn before 9 a.m. |
http://loinc.org · 2143-6 |
| S | 2016-06-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2016-08-11 | Thyrotropin [Units/volume] in Serum or Plasma | 3.6 mIU/L Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2016-08-11 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2016-08-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2016-08-11 | Glucose [Mass/volume] in Serum or Plasma | 93 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2016-08-11 | Cholesterol [Mass/volume] in Serum or Plasma | 204 mg/dL (high) Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2016-08-11 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 124 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2016-08-11 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 mg/dL Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 2016-08-11 | Triglyceride [Mass/volume] in Serum or Plasma | 110 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2016-08-11 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2016-01-05 | Body height | 165 cm | 8302-2 | S |
| 2016-01-05 | Body weight | 74.6 kg | 29463-7 | S |
| 2016-01-05 | Body mass index (BMI) [Ratio] | 27.4 kg/m2 | 39156-5 | S |
| 2016-01-05 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2016-01-05 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2016-01-05 | Heart rate | 78 /min | 8867-4 | S |
| 2016-01-05 | Respiratory rate | 16 /min | 9279-1 | S |
| 2016-01-05 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2016-01-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2016-01-20 | Body height | 165 cm | 8302-2 | S |
| 2016-01-20 | Body weight | 74.2 kg | 29463-7 | S |
| 2016-01-20 | Body mass index (BMI) [Ratio] | 27.3 kg/m2 | 39156-5 | S |
| 2016-01-20 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2016-01-20 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2016-01-20 | Heart rate | 84 /min | 8867-4 | S |
| 2016-01-20 | Respiratory rate | 16 /min | 9279-1 | S |
| 2016-01-20 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2016-01-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2016-02-24 | Body height | 165 cm | 8302-2 | S |
| 2016-02-24 | Body weight | 72.6 kg | 29463-7 | S |
| 2016-02-24 | Body mass index (BMI) [Ratio] | 26.7 kg/m2 | 39156-5 | S |
| 2016-02-24 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2016-02-24 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2016-02-24 | Heart rate | 80 /min | 8867-4 | S |
| 2016-02-24 | Respiratory rate | 16 /min | 9279-1 | S |
| 2016-02-24 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2016-02-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2016-04-28 | Body height | 165 cm | 8302-2 | S |
| 2016-04-28 | Body weight | 71.8 kg | 29463-7 | S |
| 2016-04-28 | Body mass index (BMI) [Ratio] | 26.4 kg/m2 | 39156-5 | S |
| 2016-04-28 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2016-04-28 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2016-04-28 | Heart rate | 82 /min | 8867-4 | S |
| 2016-04-28 | Respiratory rate | 16 /min | 9279-1 | S |
| 2016-04-28 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2016-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2016-06-30 | Body height | 165 cm | 8302-2 | S |
| 2016-06-30 | Body weight | 72.4 kg | 29463-7 | S |
| 2016-06-30 | Body mass index (BMI) [Ratio] | 26.6 kg/m2 | 39156-5 | S |
| 2016-06-30 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2016-06-30 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2016-06-30 | Heart rate | 64 /min | 8867-4 | S |
| 2016-06-30 | Respiratory rate | 16 /min | 9279-1 | S |
| 2016-06-30 | Body temperature | 36.4 Cel | 8310-5 | S |
| 2016-06-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2016-08-11 | Body height | 165 cm | 8302-2 | S |
| 2016-08-11 | Body weight | 73 kg | 29463-7 | S |
| 2016-08-11 | Body mass index (BMI) [Ratio] | 26.8 kg/m2 | 39156-5 | S |
| 2016-08-11 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2016-08-11 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2016-08-11 | Heart rate | 70 /min | 8867-4 | S |
| 2016-08-11 | Respiratory rate | 16 /min | 9279-1 | S |
| 2016-08-11 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2016-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Journalist and co-anchor of a nightly national news program; also moderates a weekly political program; long working days and frequent travel in an election year
- S Lives alone in Washington, D.C.; has no children. Supports: a large extended family she is close to, many friends, and her church community
- S Very private about her health: wants information shared only with the people she chooses, and wants to keep working through treatment if she can
- S Never smoker; alcohol occasionally, within low-risk limits; no drug use
- S Menstrual history: last period about eight years ago; no menopausal hormone therapy, tamoxifen or other hormone use
Functional status
- S Independent and working full time; walks most days
Mental status
- S Alert, direct and precise; asks pointed questions and wants the facts plainly; PHQ-2 negative; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day
- S Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cycles
- S Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles
- S Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine
- S Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea
- S Dostarlimab 50 mg/mL injection, 1000 mg intravenously over 30 minutes every 6 weeks as maintenance, for up to three years
- S Levothyroxine 75 mcg oral tablet, one tablet daily before breakfast
Procedures and immunizations
Procedures
- S Office endometrial biopsy with a suction catheter (Pipelle), with a chaperone, after verbal consent: adequate tissue obtained; tolerated with mild cramping
- S Transvaginal ultrasound of the pelvis: endometrium 16 mm, heterogeneous, with an irregular junction with the myometrium and internal blood flow; two small intramural fibroids (1.8 cm and 1.2 cm); ovaries normal for age; no free fluid
- S CT of the chest, abdomen and pelvis with contrast: enlarged, heterogeneous uterine cavity; a 1.5 cm right external iliac lymph node and a 1.7 cm left para-aortic lymph node below the renal veins, both suspicious; no liver, lung, bone or peritoneal lesion; no ascites
- S Advance care planning conversation, about 20 minutes
- S Screening mammogram, both breasts
- S Robotic-assisted total laparoscopic hysterectomy with removal of both fallopian tubes and ovaries and pelvic washings. Pathology: endometrioid adenocarcinoma, FIGO grade 2 (low grade), 4.2 cm, invading 65% of the myometrial thickness; no cervical stromal invasion; focal (not substantial) lymphovascular space invasion; tubes, ovaries and serosa free; washings negative. Mismatch repair deficient (loss of MLH1 and PMS2), MLH1 promoter hypermethylated, POLE wild-type, p53 wild-type; estrogen receptor positive. FIGO 2013 stage IIIC2ii, molecular class MMRd
- S Sentinel lymph node mapping with indocyanine green, both sides of the pelvis: right external iliac sentinel node with a 9 mm metastasis; left obturator sentinel node negative on ultrastaging
- S Excision of the enlarged left para-aortic lymph node seen on CT, with adjacent para-aortic nodes below the renal veins: 1 of 4 nodes involved (14 mm deposit)
- S Genetic counseling: universal Lynch syndrome tumor screening explained; MLH1 and PMS2 loss explained by MLH1 promoter hypermethylation, which is acquired in the tumor and not inherited; germline testing not indicated; she was told what would change that advice
- S CT of the chest, abdomen and pelvis with contrast at the end of combination treatment: no enlarged pelvic or para-aortic lymph node, no vaginal cuff mass, no liver, lung, bone or peritoneal lesion; expected postoperative changes (no evidence of disease)
Immunizations
- S 2016-08-11: Pneumococcal conjugate vaccine PCV20
- S 2016-08-11: Recombinant zoster vaccine, dose 1 of 2
- S 2016-08-11: Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Endometrial tissue diagnosis and ultrasound within one week, and a gynecologic oncology plan within three weeks of presentation | 2016-01-20 | completed | Biopsy at the first visit, ultrasound in two days, result in four days, CT in eight, consultation at two weeks |
| Surgical staging within four weeks of diagnosis | 2016-02-24 | completed | Minimally invasive hysterectomy with sentinel node mapping and para-aortic node removal two weeks after the consultation |
| Six cycles of dostarlimab with carboplatin and paclitaxel every three weeks without a delay of more than one week | 2016-06-30 | completed | Six cycles on schedule; CT shows no evidence of disease |
| Lynch syndrome tumor screening completed and explained before treatment starts | 2016-02-24 | completed | MLH1 promoter hypermethylation found: acquired, not inherited; genetic counseling done |
| Immune-related adverse events found early: TSH, liver tests, glucose and cortisol checked on schedule | 2016-06-30 | completed | Hypothyroidism found on a scheduled TSH and treated without stopping dostarlimab; one missed baseline cortisol recorded and corrected |
| PHQ-9 below 10 throughout treatment, with support she chooses | 2016-06-30 | completed | PHQ-9 between 4 and 6 |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Gynecologic oncology consultation within two weeks to review the endometrial biopsy and ultrasound with her and plan treatment if cancer or atypical hyperplasia is found | completed | GL-NCCN-UTERINE-2026, GL-ACOG-PMB-2026 |
| Any bleeding after menopause is evaluated: speculum and bimanual examination, office endometrial biopsy at the first visit, and transvaginal ultrasound within the week, both done rather than relying on endometrial thickness alone; blood count and A1c; results by telephone within days, not at a routine visit | completed | GL-ACOG-PMB-2026, GL-ACOG-CO734-2018, GL-DOLL-2020, GL-CLARKE-2022 |
| Staging and molecular classification: CT of the chest, abdomen and pelvis; mismatch repair immunohistochemistry and p53 on the biopsy, with MLH1 promoter methylation testing for MLH1 loss and POLE sequencing on the surgical specimen; FIGO 2013 stage with the molecular class recorded | completed | GL-NCCN-UTERINE-2026, GL-FIGO-2023, GL-CMID-2026 |
| Robotic-assisted total laparoscopic hysterectomy with removal of both tubes and ovaries, pelvic washings, sentinel lymph node mapping with indocyanine green, and removal of the enlarged pelvic and para-aortic nodes | completed | GL-NCCN-UTERINE-2026 |
| Lynch syndrome screening of the tumor for every endometrial cancer, with genetic counseling; germline testing if mismatch repair loss is not explained by MLH1 promoter methylation, and cascade testing offered to blood relatives only if a germline variant is found | completed | GL-NCCN-UTERINE-2026, GL-ACOG-PB147, GL-CMID-2026 |
| Dostarlimab 500 mg with carboplatin (AUC 5) and paclitaxel 175 mg/m2 every three weeks for six cycles, then dostarlimab 1000 mg every six weeks for up to three years, for mismatch repair deficient stage IIIC2 disease; hepatitis B, hepatitis C and HIV screening first; three-drug antiemetic prevention; blood counts, kidney function and magnesium before each cycle; TSH, free T4, liver tests, glucose and morning cortisol at baseline and before each cycle; neuropathy checks at each visit | completed | GL-NCCN-UTERINE-2026, GL-RUBY-2023, GL-JEMPERLI-LABEL, GL-ASCO-IRAE-2021, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020, GL-CMID-2026 |
| Immune-related hypothyroidism: levothyroxine with TSH and free T4 every six weeks, continuing dostarlimab | completed | GL-ASCO-IRAE-2021, GL-JEMPERLI-LABEL, GL-CMID-2026 |
| Survivorship: examination with a pelvic examination every three months for two years, CT of the chest, abdomen and pelvis every six months for three years, no routine vaginal cytology and no CA-125 (normal at diagnosis), teaching on symptoms of recurrence, lymphedema checks, sexual health, weight, activity, blood pressure, lipid and glucose care, distress screening, and age-appropriate screening for other cancers | completed | GL-SGO-SURV-2026, GL-NCCN-UTERINE-2026, GL-CMID-2026 |
| Distress and depression screening at each visit, plain explanations, written information, and support she chooses; she decides who receives each note | completed | GL-USPSTF-DEP-2023, GL-NCCN-UTERINE-2026 |
Planned encounters
- 2016-01-05 — Three weeks of postmenopausal bleeding in a woman of 60: examination, office endometrial biopsy, transvaginal ultrasound, and gynecologic oncology review booked (ENC-001)
- 2016-01-20 — Biopsy result: endometrial cancer; staging CT, gynecologic oncology consultation, Lynch syndrome tumor screening, and preparation for surgery (ENC-002)
- 2016-02-24 — Review three weeks after surgical staging: final pathology and molecular class, genetic counseling, and the first cycle of dostarlimab with carboplatin and paclitaxel (ENC-003)
- 2016-04-28 — Midpoint of combination treatment: blood counts, immune-related adverse event checks, neuropathy, and mood (ENC-004)
- 2016-06-30 — End of combination treatment: response CT, immune-related hypothyroidism, the first maintenance dostarlimab dose, and the survivorship plan (ENC-005)
- 2016-08-11 — Periodic adult preventive visit (ENC-006)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Focused Visit (Care-plan review)
- Progress note 06 — Preventive Visit
- Gynecologic Oncology referral
- Gynecologic Oncology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Focused Visit (Care-plan review) (XML)
- Progress note 06 — Preventive Visit (XML)
- Gynecologic Oncology referral (XML)
- Gynecologic Oncology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Bernstein A. Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61 (The Washington Post) | Anchorage Daily News | other |
| SRC-0002 | Byers D, Stelter B. PBS newscaster Gwen Ifill has died (CNNMoney) | KSL.com | other |
| SRC-0003 | Remembering Gwen | PBS NewsHour | other |
| SRC-0004 | Ulaby N. PBS News Anchor Gwen Ifill Dies At 61 (All Things Considered) | NPR | other |
| SRC-0005 | Ehrbar N. Gwen Ifill, "PBS NewsHour" anchor, is dead at 61 | CBS News | other |
| SRC-0006 | PBS' Gwen Ifill, on leave, expected to return in 2 weeks (The Associated Press) | InfoNews | other |
| SRC-0007 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the combined biopsy and ultrasound pathway, the FIGO 2023 stage IIIC2ii with the MMRd molecular class, the choice of dostarlimab with carboplatin and paclitaxel, MLH1 methylation instead of germline testing, the immune-related hypothyroidism managed without stopping dostarlimab, and the survivorship schedule. |
| provenance review | not_started | Recent-death rule: only what she made public, what was reported during her life, and obituaries and official statements: The Washington Post, CNN, PBS NewsHour, NPR, CBS News and the Associated Press. The stage, histology and treatment of her cancer were never made public; everything clinical is synthetic. |
| safe messaging review | not_started | No mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative is named in the modern episode, and no health fact, decision or genetic result is attributed to any real person. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.